ArticleJournal of dermato-oncology2026
Mechanistic and preclinical evaluation of SIRT3 as a therapeutic target in melanoma.
Article in Journal of dermato-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Despite advances in targeted inhibitors and immunotherapies, melanoma remains one of the deadliest skin cancers due to high metastatic potential and resistance to current therapies. This underscores a critical need for new, mechanism-based treatment strategies. Sirtuins, a family of class III histone deacetylases, have been implicated by our lab and others in numerous cellular functions, diseases, and cancers including melanoma. Here, we sought to extend our findings on the pro-proliferative role of SIRT3 by: (i) defining downstream mechanisms using PCR array and NanoString gene-expression profiling on CRISPR/Cas9-mediated SIRT3 knockout (KO) in melanoma cells; (ii) assessing effects of siRNA against SIRT3 in patient-derived xenograft (PDX) and Braf
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.